Objective: To study the relationship between 14-3-3 sigma gene promoter hypermethylation and its transcrip-tion levels in sporadic breast carcinogenesis. Methods: Hypermethylation of 14-3-3 sigma gene was detected by ...Objective: To study the relationship between 14-3-3 sigma gene promoter hypermethylation and its transcrip-tion levels in sporadic breast carcinogenesis. Methods: Hypermethylation of 14-3-3 sigma gene was detected by sensitive MSP assay in carcinous, non-cancerious and normal tissue, and its mRNA was also detected by real-time PCR based on SYBR Green 1. Results: The hypermethylation frequencies of 14-3-3 sigma were 90% in 68 cases of sporadic breast cancer patients. Hypermethylation was presented in portions (2/13,18%) of hyperplastic samples, and no hypermethylation was presented in normal tissue. The hypermethylation change of 14-3-3 sigma gene was markedly related with various types, grades and lymph node metastases (P < 0.05), and no significant differences in methylation frequencies were seen between premenopause and postmenopause (P > 0.05). The hypermethylation of 14-3-3 sigma showed reverse relationship with its mRNA transcription (P < 0.05). Only lymph node metastases was strongly associated with poor outcome (P = 0.02). Whether 14-3-3 sigma promoter methylation or not did not affect the 5-year survival rate of sporadic breast cancer (P > 0.05). Conclu-sion: Epigenetics alterations of the 14-3-3 sigma can contribute to reducing or losing the expression of 14-3-3 sigma protein, which plays an important role in the development of sporadic breast carcinomas including various types, grades and lymph node metastases.展开更多
Objective: The results of a previous study showed that a clear dysregulation was evident in the global gene expression of the BCL11A-suppressed B-lymphoma cells. In this study, the bone morphogenetic protein receptor,...Objective: The results of a previous study showed that a clear dysregulation was evident in the global gene expression of the BCL11A-suppressed B-lymphoma cells. In this study, the bone morphogenetic protein receptor, type II(BMPR2), E1 A binding protein p300(EP300), transforming growth factor-β2(TGFβ2), and tumor necrosis factor, and alpha-induced protein 3(TNFAIP3) gene expression patterns in B-cell malignancies were studied. Methods: The relative expression levels of BMPR2, EP300, TGFβ2, and TNFAIP3 mRNA in B-lymphoma cell lines, myeloid cell lines, as well as in cells from healthy volunteers, were determined by real-time quantitative reverse transcriptpolymerase chain reaction(qRT-PCR) with SYBR Green Dye. Glyceraldehyde-3-phosphate dehydrogenase(GAPDH) was used as reference. Results: The expression level of TGFβ2 mRNA in B-lymphoma cell lines was significantly higher than those in the cells from the healthy control(P<0.05). However, the expression level of TNFAIP3 mRNA in B-malignant cells was significantly lower than that of the healthy control(P<0.05). The expression levels of BMPR2 and EP300 mRNA showed no significant difference between B-malignant cell lines and the healthy group(P>0.05). In B-lymphoma cell lines, correlation analyses revealed that the expression of BMPR2 and TNFAIP3(r=0.882, P=0.04) had significant positive relation. The expression levels of BMPR2, EP300, and TNFAIP3 mRNA in cell lines from myeloid leukemia were significantly lower than those in the cells from the healthy control(P<0.05). The expression levels of TGFβ2 mRNA showed no significant difference between myeloid leukemia cell lines and the healthy control or B-malignant cell lines(P>0.05). The expression levels of BMPR2, EP300, and TNFAIP3 mRNA in B-lymphoma cells were significantly higher than those of the myeloid leukemia cells(P<0.05).Conclusion: Different expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 genes in B-lymphoma cells exist.展开更多
基金Supported by a grant from the Natural Sciences Foundation of Hubei Province (No. 2007ABA371).
文摘Objective: To study the relationship between 14-3-3 sigma gene promoter hypermethylation and its transcrip-tion levels in sporadic breast carcinogenesis. Methods: Hypermethylation of 14-3-3 sigma gene was detected by sensitive MSP assay in carcinous, non-cancerious and normal tissue, and its mRNA was also detected by real-time PCR based on SYBR Green 1. Results: The hypermethylation frequencies of 14-3-3 sigma were 90% in 68 cases of sporadic breast cancer patients. Hypermethylation was presented in portions (2/13,18%) of hyperplastic samples, and no hypermethylation was presented in normal tissue. The hypermethylation change of 14-3-3 sigma gene was markedly related with various types, grades and lymph node metastases (P < 0.05), and no significant differences in methylation frequencies were seen between premenopause and postmenopause (P > 0.05). The hypermethylation of 14-3-3 sigma showed reverse relationship with its mRNA transcription (P < 0.05). Only lymph node metastases was strongly associated with poor outcome (P = 0.02). Whether 14-3-3 sigma promoter methylation or not did not affect the 5-year survival rate of sporadic breast cancer (P > 0.05). Conclu-sion: Epigenetics alterations of the 14-3-3 sigma can contribute to reducing or losing the expression of 14-3-3 sigma protein, which plays an important role in the development of sporadic breast carcinomas including various types, grades and lymph node metastases.
基金supported by the Guangdong Province Key Foundation of Science and Technology Program (Grant No.2009B0507000029)the Guangdong Province Science and Technology Program (Grant No.2012B031800474)a grant from the Overseas Chinese Affairs Office of the State Council Key Discipline Construction Fund (Grant No.51205002)
文摘Objective: The results of a previous study showed that a clear dysregulation was evident in the global gene expression of the BCL11A-suppressed B-lymphoma cells. In this study, the bone morphogenetic protein receptor, type II(BMPR2), E1 A binding protein p300(EP300), transforming growth factor-β2(TGFβ2), and tumor necrosis factor, and alpha-induced protein 3(TNFAIP3) gene expression patterns in B-cell malignancies were studied. Methods: The relative expression levels of BMPR2, EP300, TGFβ2, and TNFAIP3 mRNA in B-lymphoma cell lines, myeloid cell lines, as well as in cells from healthy volunteers, were determined by real-time quantitative reverse transcriptpolymerase chain reaction(qRT-PCR) with SYBR Green Dye. Glyceraldehyde-3-phosphate dehydrogenase(GAPDH) was used as reference. Results: The expression level of TGFβ2 mRNA in B-lymphoma cell lines was significantly higher than those in the cells from the healthy control(P<0.05). However, the expression level of TNFAIP3 mRNA in B-malignant cells was significantly lower than that of the healthy control(P<0.05). The expression levels of BMPR2 and EP300 mRNA showed no significant difference between B-malignant cell lines and the healthy group(P>0.05). In B-lymphoma cell lines, correlation analyses revealed that the expression of BMPR2 and TNFAIP3(r=0.882, P=0.04) had significant positive relation. The expression levels of BMPR2, EP300, and TNFAIP3 mRNA in cell lines from myeloid leukemia were significantly lower than those in the cells from the healthy control(P<0.05). The expression levels of TGFβ2 mRNA showed no significant difference between myeloid leukemia cell lines and the healthy control or B-malignant cell lines(P>0.05). The expression levels of BMPR2, EP300, and TNFAIP3 mRNA in B-lymphoma cells were significantly higher than those of the myeloid leukemia cells(P<0.05).Conclusion: Different expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 genes in B-lymphoma cells exist.
